Please login to the form below

Not currently logged in


This page shows the latest Waylivra news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca and Ionis sign $3.6bn deal for eplontersen

AstraZeneca and Ionis sign $3.6bn deal for eplontersen

It currently has three marketed products – Spinraza (nusinersen) for spinal muscular atrophy, Tegsedi (inotersen) for ATTR and Waylivra (volanesorsen) for familial chylomicronaemia syndrome – as well as ‘a premier late-stage pipeline’.

Latest news

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation